Data on Provectus's PV-10 For Metastatic Melanoma Presented at the 2011 International Melanoma Congress

Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced that data and study design features on PV-10 for metastatic melanoma were presented at the 2011 International Melanoma Congress on November 12, 2011, during the 5th Meeting of Interdisciplinary Melanoma/Skin Cancer Centres meeting, in Tampa, Florida. Data were presented by a Principal Investigator for Provectus's Phase 2 melanoma study, Professo...continued PVCT  cancer pharmaceuticals research

URL: http://www.investorpoint.com/news/OTCBULLB/46108887/